These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10407922)

  • 1. [Success of new treatments for schizophrenics, as shown by the example of modern antipsychotic drugs].
    Lambert M; Naber D; Perro C; Moritz S; Krausz M
    Psychiatr Prax; 1999 Apr; 26 Suppl 1():S30-5. PubMed ID: 10407922
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of schizophrenia with "atypical antipsychotic drugs". Quality of life as a measure of treatment success].
    Krankenpfl J; 2002; 40(7-9):230-1. PubMed ID: 12514869
    [No Abstract]   [Full Text] [Related]  

  • 3. [Subjective well-being under antipsychotic treatment and its meaning for compliance and course of disease].
    Naber D; Lambert M; Karow A
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S230-2. PubMed ID: 15586315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of novel antipsychotic drugs on quality of life among people suffering from schizophrenia.
    Jukić V; Barić V; Culav-Sumić J; Herceg M; Majdancić Z; Werft-Cop M
    Coll Antropol; 2003; 27 Suppl 1():119-24. PubMed ID: 12955901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New generation antipsychotic drugs and compliance behaviour.
    Voruganti LP; Baker LK; Awad AG
    Curr Opin Psychiatry; 2008 Mar; 21(2):133-9. PubMed ID: 18332660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The changing drug therapy of schizophrenia].
    Koponen H
    Duodecim; 1997; 113(24):2617-22. PubMed ID: 10892175
    [No Abstract]   [Full Text] [Related]  

  • 7. [Current concepts of pharmacological treatment in schizophrenia].
    Jarema M
    Psychiatr Pol; 2002; 36(6):857-68. PubMed ID: 12725017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term phase of schizophrenia: impact of atypical agents.
    Naber D
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S11-4. PubMed ID: 11252518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adherence to antipsychotic medication in schizophrenia patients].
    Baloush-Kleinman V; Poyurovsky M; Koren D; Schneidman M; Weizman A; Shnitt D
    Harefuah; 2002 Dec; 141(12):1042-9, 1090. PubMed ID: 12534202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to medication and quality of life in people with schizophrenia: results of a European multicenter study.
    Puschner B; Born A; Giessler A; Helm H; Leese M; Bindman JP; Gray RJ; Schene A; Kikkert M; Burti L; Marrella G; Becker T
    J Nerv Ment Dis; 2006 Oct; 194(10):746-52. PubMed ID: 17041286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of atypical antipsychotic medications in the treatment of psychosis.
    White DL
    Kans Nurse; 2003; 78(10):1-2. PubMed ID: 14746070
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonadherence to antipsychotic treatment in patients with schizophrenic disorders.
    Svestka J; Bitter I
    Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():95-116. PubMed ID: 17262005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.
    Wehmeier PM; Kluge M; Schneider E; Schacht A; Wagner T; Schreiber W
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):703-12. PubMed ID: 17289237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia.
    Holzinger A; Loffler W; Muller P; Priebe S; Angermeyer MC
    J Nerv Ment Dis; 2002 Sep; 190(9):597-603. PubMed ID: 12357093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between patient satisfaction and treatment outcomes in schizophrenia.
    Chue P
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):38-56. PubMed ID: 17046986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Course of adherence to medication and quality of life in people with schizophrenia.
    Puschner B; Angermeyer MC; Leese M; Thornicroft G; Schene A; Kikkert M; Burti L; Tansella M; Becker T
    Psychiatry Res; 2009 Feb; 165(3):224-33. PubMed ID: 19155070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clozapine maintenance therapy in schizophrenia.
    Gaszner P; Makkos Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.